Hao Shao

Dr. Hao Shao

College of Pharmaceutical Science, Southwest University, Chongqing, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
EPEuan S. Polson
Euan S. Polson
VKVerena B. Kuchler
Verena B. Kuchler
CAChristopher Abbosh
Christopher Abbosh
EREdith M. Ross
Edith M. Ross
RMRyan K Mathew
Ryan K Mathew
HWHeiko Wurdak
Heiko Wurdak
Modulation of energy metabolism with the small-molecule KHS101 promoted tumor-selective death of human glioblastoma cells and reduced tumor growth in mice.

10 March 2020 in Science Signaling
Verified
Journal Article
Closed access
Pui Kei WuPui Kei Wu
Pui Kei Wu
SHSeung-Keun Hong
Seung-Keun Hong
WCWenjing Chen
Wenjing Chen
ABAndrew E. Becker
Andrew E. Becker
RGRebekah Gundry
Rebekah Gundry
JPJong-In Park
Jong-In Park
Blocking the heat shock chaperone mortalin kills BRAF-mutant and MEK-ERK pathway–driven tumor cells.

7 June 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
AGAmelia A. Glazier
Amelia A. Glazier
NHNeha Hafeez
Neha Hafeez
DMDattatreya Mellacheruvu
Dattatreya Mellacheruvu
VBVenkatesha Basrur
Venkatesha Basrur
ANAlexey I. Nesvizhskii
Alexey I. Nesvizhskii
SDSharlene M. Day
Sharlene M. Day
Cardiac myosin binding protein C ( MYBPC3 ) is the most commonly mutated gene associated with hypertrophic cardiomyopathy (HCM). Haploinsufficiency of full-length MYBPC3 and disruption of proteostasis have both been proposed as central to HCM disease pathogenesis. Discriminating the relative contributions of these 2 mechanisms requires fundamental knowledge of how turnover of WT and mutant MYBPC3 proteins is regulated. We expressed several disease-causing mutations in MYBPC3 in primary neonatal rat ventricular cardiomyocytes. In contrast to WT MYBPC3, mutant proteins showed reduced expression and failed to localize to the sarcomere. In an unbiased coimmunoprecipitation/mass spectrometry screen, we identified HSP70-family chaperones as interactors of both WT and mutant MYBPC3. Heat shock cognate 70 kDa (HSC70) was the most abundant chaperone interactor. Knockdown of HSC70 significantly slowed degradation of both WT and mutant MYBPC3, while pharmacologic activation of HSC70 and HSP70 accelerated degradation. HSC70 was expressed in discrete striations in the sarcomere. Expression of mutant MYBPC3 did not affect HSC70 localization, nor did it induce a protein folding stress response or ubiquitin proteasome dysfunction. Together these data suggest that WT and mutant MYBPC3 proteins are clients for HSC70, and that the HSC70 chaperone system plays a major role in regulating MYBPC3 protein turnover.

3 August 2020 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
RBRocio Bengoechea
Rocio Bengoechea
AFAndrew R. Findlay
Andrew R. Findlay
ABANKAN KUMAR BHADRA
ANKAN KUMAR BHADRA
Hao ShaoHao Shao
Hao Shao
KSKevin C. Stein
Kevin C. Stein
CWConrad Weihl
Conrad Weihl
Dominant mutations in the HSP70 co-chaperone DNAJB6 cause a late onset muscle disease termed limb girdle muscular dystrophy type D1 (LGMDD1), which is characterized by protein aggregation and vacuolar myopathology. Disease mutations reside within the G/F domain of DNAJB6, but the molecular mechanisms underlying dysfunction are not well understood. Using yeast, cell culture, and mouse models of LGMDD1, we found that the toxicity associated with disease-associated DNAJB6 required its interaction with HSP70, and that abrogating this interaction genetically or with small molecules was protective. In skeletal muscle, DNAJB6 localizes to the Z-disc with HSP70. Whereas HSP70 normally diffused rapidly between the Z-disc and sarcoplasm, the rate of HSP70’s diffusion in LGMDD1 mouse muscle was diminished likely because it has an unusual affinity for the Z-disc and mutant DNAJB6. Treating LGMDD1 mice with a small molecule inhibitor of the DNAJ-HSP70 complex re-mobilized HSP70, improved strength and corrected myopathology. These data support a model in which LGMDD1 mutations in DNAJB6 are a gain-of-function disease that is, counter-intuitively, mediated via HSP70 binding. Thus, therapeutic approaches targeting HSP70:DNAJB6 may be effective in treating this inherited muscular dystrophy.

1 April 2016 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
RKRonik Khachatoorian
Ronik Khachatoorian
RRRana Riahi
Rana Riahi
EGEkambaram Ganapathy
Ekambaram Ganapathy
Hao ShaoHao Shao
Hao Shao
NWNicole M. Wheatley
Nicole M. Wheatley
SFSamuel W. French
Samuel W. French

1 March 2020 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
Hao ShaoHao Shao
Hao Shao
JGJason E. Gestwicki
Jason E. Gestwicki